Company Performance - Natera reported a quarterly loss of $0.50 per share, which was better than the Zacks Consensus Estimate of a loss of $0.59, and an improvement from a loss of $0.56 per share a year ago, representing an earnings surprise of 15.25% [1] - The company posted revenues of $501.83 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 13.19%, and showing a significant increase from year-ago revenues of $367.74 million [2] - Natera has surpassed consensus EPS estimates in all four of the last quarters [2] Stock Outlook - The immediate price movement of Natera's stock will largely depend on management's commentary during the earnings call and future earnings expectations [3] - Natera shares have increased by approximately 1.1% since the beginning of the year, contrasting with a decline of -4.3% in the S&P 500 [3] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is -$0.52 on revenues of $460.85 million, and for the current fiscal year, it is -$2.02 on revenues of $1.92 billion [7] - The estimate revisions trend for Natera is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical Services industry, to which Natera belongs, is currently ranked in the top 22% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, IceCure Medical Ltd. (ICCM), is expected to report a quarterly loss of $0.08 per share, with revenues projected at $0.75 million, reflecting a 1.4% increase from the year-ago quarter [9]

Financial Data and Key Metrics Changes - The company generated $520 million in revenue for Q1 2025, representing approximately 37% growth compared to $368 million in Q1 2024 [7][32] - Gross margins improved to 63% in Q1 2025, up from 52% a year ago, with underlying gross margin improvement of about 110 basis points from Q4 2024 [8][33] - The company generated $23 million in cash during the quarter while increasing investments in growth [8][20] Business Line Data and Key Metrics Changes - Women's Health volumes increased significantly, with over 40,000 units processed sequentially in Q1 2025 compared to Q4 2024 [14][81] - Organ Health saw over 50% year-on-year growth, driven by interest in donor-derived cell-free DNA tests [14] - Signatera clinical volumes grew 52% year-on-year, with a record increase of approximately 16,500 units compared to Q4 2024 [8][15] Market Data and Key Metrics Changes - The company processed 855,000 tests in Q1 2025, an 8% sequential increase over Q4 2024 [13] - The oncology segment is seeing significant growth, with over 45% of oncologists in the U.S. ordering Signatera tests last quarter [16] - The company expects revenues for the full year to be in the range of $1.94 billion to $2.02 billion, reflecting a $70 million increase from prior guidance [9] Company Strategy and Development Direction - The company is focused on expanding clinical utility and innovating to help more patients, particularly in oncology [16][21] - There is a strategic emphasis on increasing average selling prices (ASPs) through improved reimbursement operations and expanding into new tumor types [18][20] - The company aims to achieve gross margins above 70% over time, with significant potential opportunities identified [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of volume growth and ASP improvements, despite potential short-term headwinds from new product launches [35][36] - The company views 2025 as a crucial investment year, particularly for Signatera, with expectations of continued strong cash flow generation [20][37] - Management highlighted the importance of upcoming clinical data presentations at major conferences, which are expected to drive further growth [25][29] Other Important Information - The company has maintained a strong balance sheet with nearly $1 billion in cash and no debt outside of a line of credit [33] - The DEFINE study in heart transplantation demonstrated Prospera's ability to predict clinical outcomes, outperforming traditional biopsy methods [10][22] - The company is preparing for significant data presentations at ASCO, with nearly 30 abstracts planned across multiple tumor types [28][29] Q&A Session Summary Question: What drove the sequential volume growth in Signatera? - Management noted that strong clinical utility and data performance resonated with physicians, contributing to record growth [42] Question: Which clinical studies should be focused on for potential market impact? - Management highlighted the I SPY two trial and the DARE study as significant upcoming studies that could influence market volumes [45][46] Question: Were there any disruptions in Q1 due to weather or calendar dynamics? - Management acknowledged weather challenges but indicated that patient demand for tests remained strong, minimizing impact on volumes [54][56] Question: What is the outlook for ASPs and reimbursement? - Management expects stable ASPs in women's and organ health, with modest improvements in Signatera driven by increased Medicare Advantage coverage [74] Question: Can you provide an update on the colorectal screening front? - Management confirmed that the PRESIDE study has met its enrollment goals and will report results by the end of the year, with an FDA enabling study also underway [67][68]

Financial Data and Key Metrics Changes - The company generated $520 million in revenue for Q1 2025, representing approximately 37% growth compared to $368 million in Q1 2024 [5][6][14] - Gross margins improved to 63% in Q1 2025, up from 39% in previous quarters, with an underlying gross margin improvement of about 110 basis points from 59.3% in Q4 2024 to 60.4% in Q1 2025 [15][16][30] - The company generated $23 million in cash during the quarter, indicating strong cash flow generation despite increased investments in growth [6][17][30] Business Line Data and Key Metrics Changes - Women's Health volumes grew significantly, with over 40,000 units processed sequentially in Q1 2025, continuing strong growth from 2024 [12][30] - Organ Health saw over 50% year-on-year growth, driven by interest in donor-derived cell-free DNA and germline tests [12][30] - Signatera clinical volumes grew 52% year-on-year, with a record increase of approximately 16,500 units compared to Q4 2024 [6][13][14] Market Data and Key Metrics Changes - The company processed 855,000 tests in Q1 2025, an 8% sequential increase over Q4 2024 [11][12] - The oncology market is expanding, with over 45% of oncologists in the U.S. ordering Signatera tests last quarter [13][14] - The company anticipates that Signatera could eventually generate more than $5 billion in annual revenue, reflecting significant market potential [17][30] Company Strategy and Development Direction - The company is focused on expanding clinical utility and innovating to help more patients, particularly in oncology and women's health [13][17] - The company plans to continue funding high return on invested capital (ROIC) investments in commercial operations, clinical trials, and product improvements [17][30] - The company aims to achieve gross margins above 70% over time, with ongoing improvements in average selling prices (ASPs) and cost of goods sold (COGS) [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of revenue growth, driven by strong clinical utility and data generated from studies [41][42] - The company is optimistic about upcoming data presentations at major conferences, which are expected to enhance market presence and drive future growth [43][44] - Management highlighted the importance of maintaining cash flow breakeven while investing in growth opportunities, particularly in oncology [30][34] Other Important Information - The company raised its revenue guidance for 2025 to a range of $1.94 billion to $2.02 billion, reflecting a $70 million increase from previous guidance [7][31] - The company is preparing for significant data presentations at ASCO and ESMO conferences, with nearly 30 abstracts planned [25][26] - The company is also pursuing expansion into new histologies, including sarcoma, which presents a significant clinical unmet need [24][25] Q&A Session Summary Question: What drove the sequential volume growth in Signatera? - Management noted that strong clinical utility and a large commercial presence contributed to the record sequential growth, with expectations for continued utilization [40][41] Question: Which clinical studies should be focused on for potential volume growth? - Management highlighted the I SPY two trial and the DARE study as significant upcoming studies that could impact volumes positively [42][43] Question: Did weather or calendar dynamics affect Q1 performance? - Management acknowledged that weather challenges existed but did not significantly impact volumes, as patients still sought necessary tests [54][56] Question: What is the outlook for ASPs and reimbursement? - Management indicated stable ASPs in women's health and organ health, with modest improvements expected in Signatera due to increased reimbursement rates [71][75] Question: What is the status of the colorectal screening study? - Management confirmed that the PRESIDE study has met its enrollment goals and results are expected by the end of the year [67][68]

Financial Performance - Revenue reached $502 million in Q1 2025, a 37% increase compared to $368 million in Q1 2024[9] - Gross margin was 63% in Q1 2025, up from 57% in Q1 2024, with approximately $23 million in cash inflow generated[9] - The company is increasing its 2025 financial outlook, projecting revenue of $1.94 billion - $2.02 billion, representing a pro-forma revenue growth of approximately 26%, with a gross margin of 60% - 64% and positive cash flow generation[9] Volume and Test Growth - Total tests processed in Q1 2025 reached 855K, a 16% increase compared to 736K in Q1 2024[9] - Clinical oncology tests saw significant growth, with 161K tests in Q1 2025, a 52% increase compared to 106K in Q1 2024[9] - Signatera clinical units experienced substantial sequential growth, increasing by approximately 165K units compared to Q4 2024[14] Product and Clinical Data Highlights - Prospera Heart demonstrated strong performance with donor quantity score (DQS) in detecting allograft rejection, as published in the American Journal of Transplantation, showing an 8357% specificity[22] - The DEFINE-HT clinical trial showed that patients with elevated Prospera had a significantly higher risk for adverse events (HR: 256, p=00299)[24] - In the I-SPY 2 breast cancer trial, Signatera quantification was identified as a significant risk factor for recurrence[30] - A sarcoma study with over 200 patients and 2100 samples showed 89% sensitivity and 100% specificity overall, and 93% sensitivity and 100% specificity for Leiomyosarcoma[33]

[Overview and Highlights](index=1&type=section&id=Recent%20Strategic%20and%20Financial%20Highlights) [Q1 2025 Highlights](index=1&type=section&id=Recent%20Strategic%20and%20Financial%20Highlights) Natera reported strong Q1 2025 results, with revenue up 36.5% to $501.8 million, gross margin at 63.1%, and positive cash flow - CEO highlighted strong volume growth, including record Signatera test performance, driven by technology and clinical data strength[3](index=3&type=chunk) Q1 2025 Key Performance Indicators | Metric | Q1 2025 | Q1 2024 | % Change | | :--- | :--- | :--- | :--- | | Total Revenues (Millions USD) | $501.8 | $367.7 | +36.5% | | Gross Margin (%) | 63.1% | 56.7% | +6.4 p.p. | | Total Tests Processed (Units) | ~855,100 | ~735,800 | +16.2% | | Oncology Tests Performed (Units) | ~167,700 | ~114,800 | +46.1% | | Cash Flow (Millions USD) | $23.2 | N/A | N/A | [Financial Performance](index=1&type=section&id=First%20Quarter%20Ended%20March%2031%2C%202025%20Financial%20Results) [Q1 2025 Financial Results](index=1&type=section&id=First%20Quarter%20Ended%20March%2031%2C%202025%20Financial%20Results) Natera's Q1 2025 revenues grew 36.5% to $501.8 million, gross margin expanded to 63.1%, and net loss was $66.9 million Q1 2025 vs Q1 2024 Financial Summary | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Total Revenues (Thousands USD) | $501,830 | $367,741 | | Gross Profit (Thousands USD) | $316,800 | $208,600 | | Gross Margin (%) | 63.1% | 56.7% | | Loss from Operations (Thousands USD) | ($79,177) | ($74,314) | | Net Loss (Thousands USD) | ($66,936) | ($67,599) | | Diluted Net Loss per Share (USD) | ($0.50) | ($0.56) | - Product revenue growth was driven by higher test volumes, improved average selling price, and prior period cash collections[3](index=3&type=chunk) - Operating expenses increased due to headcount growth for new products, along with higher consulting and legal costs[7](index=7&type=chunk) [Test Volume Analysis](index=1&type=section&id=Test%20Volume%20Summary) Q1 2025 test volumes grew, with total tests processed up 16.2% to 855,100 and tests reported increasing 18.5% Test Volume Breakdown (Q1 2025 vs Q1 2024) | Unit | Q1 2025 | Q1 2024 | % Change | | :--- | :--- | :--- | :--- | | Tests processed (Units) | 855,100 | 735,800 | +16.2% | | Tests accessioned (Units) | 840,800 | 718,700 | +17.0% | | Tests reported (Units) | 804,800 | 679,400 | +18.5% | - Oncology tests significantly drove growth, increasing **46.1% year-over-year** to approximately **167,700 tests** in Q1 2025[4](index=4&type=chunk) [Financial Position and Cash Flow](index=1&type=section&id=Financial%20Position%20and%20Cash%20Flow) Natera ended Q1 2025 with strong liquidity of $991.6 million in cash and equivalents, achieving positive cash flow - Achieved positive cash flow of approximately **$23.2 million** in Q1 2025, from **$44.5 million** operating cash flow and **$0.5 million** financing cash flow, offset by **$21.8 million** capital expenditures[4](index=4&type=chunk)[19](index=19&type=chunk) Cash and Debt Position | Metric | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, equivalents, investments, restricted cash (Millions USD) | $991.6 | $968.3 | | Total outstanding debt (Millions USD) | $80.3 | N/A | [2025 Financial Outlook](index=2&type=section&id=Financial%20Outlook) [Full-Year 2025 Guidance](index=2&type=section&id=Financial%20Outlook) Natera projects 2025 total revenues of **$1.94 billion to $2.02 billion**, gross margins of **60-64%**, and positive net cash inflow 2025 Financial Guidance | Metric | 2025 Guidance | | :--- | :--- | | Total Revenue (Billions USD) | $1.94 to $2.02 | | Gross Margin (% of Revenues) | ~60% to 64% | | Selling, General & Administrative Costs (Billions USD) | $0.975 to $1.05 | | Research & Development Costs (Millions USD) | $550 to $590 | | Net Cash Inflow | Positive | [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, Natera's total assets were **$1.73 billion**, liabilities **$492.7 million**, and stockholders' equity **$1.24 billion** Balance Sheet Summary (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Total current assets (Thousands USD) | $1,416,385 | $1,375,820 | | **Total assets (Thousands USD)** | **$1,732,366** | **$1,660,735** | | Total current liabilities (Thousands USD) | $365,677 | $344,045 | | **Total liabilities (Thousands USD)** | **$492,691** | **$465,315** | | **Total stockholders' equity (Thousands USD)** | **$1,239,675** | **$1,195,420** | [Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Q1 2025 total revenues were **$501.8 million**, with a net loss of **$66.9 million**, an improvement from **$67.6 million** net loss in Q1 2024 Statement of Operations Summary (in thousands, except per share data) | Account | Three months ended March 31, 2025 | Three months ended March 31, 2024 | | :--- | :--- | :--- | | Total revenues (Thousands USD) | $501,830 | $367,741 | | Total cost and expenses (Thousands USD) | $581,007 | $442,055 | | Loss from operations (Thousands USD) | ($79,177) | ($74,314) | | **Net loss (Thousands USD)** | **($66,936)** | **($67,599)** | | **Net loss per share (USD)** | **($0.50)** | **($0.56)** | [Other Information](index=3&type=section&id=Other%20Information) [About Natera](index=3&type=section&id=About%20Natera) Natera is a global leader in cell-free DNA and genetic testing, focusing on oncology, women's health, and organ health - Natera's core business areas include oncology, women's health, and organ health, leveraging cell-free DNA and genetic testing[12](index=12&type=chunk) [Forward-Looking Statements and Risk Factors](index=3&type=section&id=Forward-Looking%20Statements) Forward-looking statements are subject to risks including financial goals, competition, product performance, reimbursement, and FDA LDT regulations - Report projections are forward-looking, based on current estimates, and not guarantees of future performance[14](index=14&type=chunk) - Significant risks include competition, reimbursement challenges, product liability, and compliance costs with governmental regulations like FDA LDT rules[15](index=15&type=chunk)

Core Viewpoint - Enhabit (EHAB) reported quarterly earnings of $0.10 per share, exceeding the Zacks Consensus Estimate of $0.07 per share, marking a 42.86% earnings surprise compared to the previous year's earnings of $0.07 per share [1] Financial Performance - Enhabit posted revenues of $259.9 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.56% and down from $262.4 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [2] Stock Performance - Enhabit shares have increased by approximately 2.9% since the beginning of the year, contrasting with the S&P 500's decline of -4.7% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $267.14 million, and for the current fiscal year, it is $0.37 on revenues of $1.07 billion [7] - The estimate revisions trend for Enhabit is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which Enhabit belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Core Insights - Pediatrix Medical Group reported quarterly earnings of $0.33 per share, exceeding the Zacks Consensus Estimate of $0.25 per share, and showing an increase from $0.20 per share a year ago, representing a 32% earnings surprise [1] - The company achieved revenues of $458.36 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.86%, although this is a decrease from $495.1 million in the same quarter last year [2] - The stock has lost approximately 1.3% since the beginning of the year, while the S&P 500 has declined by 3.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $466.24 million, and for the current fiscal year, it is $1.55 on revenues of $1.88 billion [7] - The estimate revisions trend for Pediatrix Medical Group is favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which Pediatrix Medical Group belongs, is currently ranked in the top 25% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Financial Data and Key Metrics Changes - Revenues for Q4 2024 were $476 million, representing a 53% year-on-year increase and exceeding the pre-announcement of $472 million by $4 million [10] - Volumes increased by 26% compared to Q4 of the previous year, with gross margins improving to 63% from 51% a year ago [10][19] - Cash flow generated in Q4 was approximately $46 million, contributing to a total of about $86 million for the full year [11][21] Business Line Data and Key Metrics Changes - Women's health saw strong organic growth, bolstered by new features and datasets, while organ health volumes rose nearly 50% year-on-year [14] - Signatera clinical volumes surged approximately 60% compared to Q4 2023, with nearly 15,000 units growth over Q3 2024 [15] - Average selling prices (ASPs) for Signatera improved to roughly $1,100 in Q4, with steady progress noted for Panorama and Horizon ASPs [16] Market Data and Key Metrics Changes - The company reported significant advancements in reimbursement coverage, including a strong increase in the Medicare ADLT rate and new coverage policies from commercial health plans [24][26] - The NCCN guidelines have strengthened the position of cell-free DNA testing across various tumor types, enhancing the accessibility of Signatera [13][45] Company Strategy and Development Direction - The company aims to reinvest generated cash flows into the business to enhance growth profiles in 2026 and beyond, focusing on expanding payer coverage and leveraging data insights [22][23] - Natera is deploying AI tools to optimize claims processing and improve operational efficiency, which is expected to enhance customer experience and product performance [29][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing momentum into 2025, with expectations for continued volume growth and stable ASPs across business lines [70] - The guidance for 2025 anticipates revenues between $1.87 billion and $1.95 billion, based on positive trends observed in recent quarters [69] Other Important Information - The company retired convertible notes early in Q4, leaving it with nearly $1 billion in cash and effectively no debt aside from a line of credit [68] - Significant clinical trial results are anticipated in 2025, which could further drive adoption and revenue growth [52] Q&A Session Summary Question: Potential for Signatera ASPs to reach around $2,000 - Management indicated that as more coverage policies are established, revenue per test could effectively double, aligning with the potential for higher ASPs over time [87] Question: Volume growth expectations for Signatera in 2025 - Management noted that while the guidance is set above the previous target of 8,000 to 10,000 units per quarter, they expect to see strong volume growth, potentially reaching levels seen in 2024 [100][102] Question: True-ups and their impact on future guidance - Management explained that true-ups are expected to moderate over time as cash collections improve, but they do not guide on true-ups due to their unpredictable nature [108][109] Question: Feedback on genome-based products from the oncology community - Positive feedback has been received from both the academic and pharmaceutical communities regarding the new genome-based products, which are seen as valuable for clinical research [118]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $16.8 million, a 15% decrease from $19.7 million in Q4 2023, primarily due to lower volume from Natera and the VA MVP program [38][39] - Full year 2024 revenue was $84.6 million, representing a 15% increase compared to $73.5 million in 2023, driven by a 60% year-over-year growth in biopharma revenue [13][43] - Gross margin for Q4 2024 was 27.1%, up from 26.5% in Q4 2023, while full year gross margin improved to 31.7% from 24.8% in 2023 [40][44] - Net loss for Q4 2024 was $16.4 million, reduced from $26.6 million in Q4 2023, and the full year net loss was $81.3 million compared to $108.3 million in 2023 [42][47] Business Line Data and Key Metrics Changes - Biopharma revenue increased by 60% year-over-year, significantly contributing to overall revenue growth, particularly from Moderna's Phase 3 melanoma trial [13][43] - The company delivered 1,441 molecular tests in Q4 2024, a 52% increase from 945 tests in Q3 2024, indicating strong demand for the NeXT Personal test [21] Market Data and Key Metrics Changes - The MRD testing market is projected to mature into a $20 billion market, with Personalis positioned for success through its ultra-sensitive MRD test, NeXT Personal [8] - The company expects to achieve Medicare reimbursement for at least two indications in 2025, focusing on breast cancer, lung cancer, and immunotherapy monitoring [24][25] Company Strategy and Development Direction - The company has laid out a multiyear strategy focused on winning in the MRD testing market, with plans to ramp up clinical volume and achieve reimbursement [19][35] - A long-term extension of the agreement with Moderna is expected to be a key driver of revenue growth over the next decade [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, anticipating continued test volume growth of 30% to 40% each quarter until reimbursement is achieved [22][35] - The company aims to deepen clinical evidence and achieve reimbursement for its tests, with a robust pipeline of over 20 studies in progress [26][30] Other Important Information - The company raised approximately $115 million in 2024 through strategic investments, enhancing its liquidity position with $185 million in cash at year-end [18][48] - Operating expenses for the full year 2024 were reduced to $95.1 million from $128.1 million in 2023, primarily due to headcount reductions [45] Q&A Session Summary Question: Should we read into the guidance that there are continuing Natera revenues? - The guidance includes revenue from both Natera and other enterprise customers, with the VA contract contributing approximately $7.5 million to $8 million [54] Question: What is the number of customers using the NeXT Dx test and the reorder rate? - Approximately 300 doctors used the test last quarter, with a high retention rate in the high 90s [56][58] Question: How should we think about the phasing of the top line for 2025? - Revenue is expected to be split approximately half in the first half and half in the second half of 2025, with biopharma revenue skewed towards the second half [63] Question: What is the expected impact on gross margins due to unreimbursed tests? - The gross margin guidance for 2025 is 21% to 23%, with significant headwinds expected from unreimbursed test costs [66] Question: Will the company look to the capital markets this year? - The company has sufficient capital to reach cash flow break-even and will evaluate the need for additional capital based on business developments [83]